首页> 美国卫生研究院文献>Theranostics >Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites
【2h】

Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites

机译:白细胞介导的纳米药物在炎症和肿瘤部位的传递

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanotechnology has become a powerful tool to potentially translate nanomedicine from bench to bedside. Nanotherapeutics are nanoparticles (NPs) loaded with drugs and possess the property of tissue targeting after surfaces of NPs are bio-functionalized. Designing smaller size of nanotherapeutics is presumed to increase tumor targeting based on the EPR (enhanced permeability and retention) effect. Since the immune systems possess a defence mechanism to fight diseases, there is an emerging concept that NPs selectively target immune cells to mediate the active delivery of drugs into sites of disease. In this review, we will focus on a key question of how nanotherapeutics specifically target immune cells and hijack them as a delivery vehicle to transport nanotherapeutics into disease tissues, thus possibly improving current therapies in inflammation, immune disorders and cancers. We will also discuss the challenges and opportunities for this new strategy of leukocyte-mediated delivery of nanotherapeutics.
机译:纳米技术已成为一种强大的工具,可以将纳米医学从实验台转化为床头。纳米治疗剂是载有药物的纳米颗粒(NPs),在NPs表面被生物功能化后具有靶向组织的特性。据推测,设计较小尺寸的纳米治疗药物可提高基于EPR(增强的通透性和保留力)作用的肿瘤靶向性。由于免疫系统具有抵抗疾病的防御机制,因此出现了一个新概念,即NPs选择性靶向免疫细胞以介导药物向疾病部位的主动传递。在这篇综述中,我们将集中讨论一个关键问题,即纳米疗法如何专门针对免疫细胞,并劫持它们作为将纳米疗法运送到疾病组织中的传递工具,从而有可能改善炎症,免疫疾病和癌症的现有疗法。我们还将讨论这种新策略的白细胞介导的纳米药物治疗的挑战和机遇。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号